The most powerful approach for studying long-term effects from ambient air pollution on health is the long-term prospective follow-up of well-defined population-based cohorts with well-characterized air pollution exposure information (European Science Foundation 1998). There are currently only five cohort studies in adults, with published results, that address the long-term impact of air pollution (Abbey et al. 1999; Dockery et al. 1993; Finkelstein et al. 2004; Hoek et al. 2002; Pope et al. 2002; . All studies but one are based in the US and three of them (Dockery et al. 1993; Hoek et al. 2002; Pope et al. 2002) , have only published findings related to mortality. The relation of longterm exposure to air pollution with respiratory and cardiovascular health and morbidity has yet to be measured in a large prospective cohort study in Europe. The large European Community Respiratory Health Survey (ECRHS) de-signed to measure natural history and risk factors for respiratory diseases (particularly asthma and allergy) across Europe has recently included air pollution exposure assessment in its protocol (Burney et al. 1994; Hazenkamp-von Arx et al. 2004 ). However, the Swiss Cohort Study on Air Pollution and Lung Diseases in Adults (SAPALDIA) is the only prospective cohort study of respiratory and cardiovascular health in adults in Europe with detailed individual residential exposure histories as a key element of the assessment of effects from long-term exposure to air pollution. The SAPALDIA cohort is a random population sample of 9 561 adults recruited and examined in 1991 (for detailed description of methods see (Martin et al. 1997) ). There were extensive health examinations, a detailed assessment of personal risk factors, assessment of average exposure to the pollutants O 3 , NO 2 , SO 2 and PM 10 in ambient air and assessment of individual exposure to NO 2 . Findings from the study showed effects from passive smoking exposure on respiratory symptoms (Leuenberger et al. 1994 ) and from air pollutant on lung function and symptoms Schindler et al. 1998; 2001; Zemp et al. 1999) and from occupational exposure and atopy on bronchial responsiveness Schwartz et al. 2002) . References values from lung function (Brändli et al. 1996; and the prevalence of atopy and allergic symptoms have been described (Strupler et al. 1997; Wüthrich et al. 1995; 1996; . Monitoring of air pollutants, meteorology and pollen has been conducted in all study areas since 1991. Regular mailings to the 9 651 original participants has ensured that changes in residential address and deaths (n = 283) amongst participants since 1991 have been updated. Of the surviving 9 368 participants, 93 % (8 715) could be traced between [2001] [2002] [2003] . This paper describes the health examinations, the bio bank, the environmental monitoring, and the assessment of air pollution exposure and basic characteristics of the participants in SAPALDIA 2.
Methods
The milestones of the SAPALDIA study (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) The eight study areas (Geneva, Basel, Lugano, Aarau, Wald, Payerne, Davos, Montana) were chosen to represent the variety of environmental conditions in respect to geography, climate, degree of urbanisation and air pollution in Switzerland. From the local registries of inhabitants of these areas random population samples of persons aged 18-60 years, who had been residents in the respective area for at least three years, were then drawn (Martin et al. 1997 ).
Health examinations were conducted at the eight local centres over the course of one year in 1991 and repeated in 2002. Detailed description of the 1991 examinations can be found elsewhere (Martin et al. 1997) . Contact with the 9 651 participants of SAPALDIA 1 (including monitoring of mortality) has been facilitated by regular mailings and updates every 1.5 years through the information collected from participants by mail or from local registries of inhabitants. The residential history database was checked at the local registries in all study areas in 1998 and 1999.
Recruitment for the SAPALDIA follow-up (2001 SAPALDIA follow-up ( -2003 Extensive efforts were made to contact all original participants of SAPALDIA 1 for the follow-up examination in SAPALDIA 2. A letter of invitation describing the health examinations, was sent to all former participants who could be traced. The letter contained a screening questionnaire (with 13 questions about respiratory symptoms, smoking, date of birth and address) and a prepaid addressed envelope for the return of the response to the local study centre. Up to three letters were sent and up to 12 telephone calls made (at different times during the day including morning, noon, evening and weekends) in an attempt to contact the nonresponders. In non-responding subjects without telephone number, SAPALDIA personnel made home visits. If all attempts to make contact failed; the subject was considered to be untraceable (n = 653, 6.8 %). The protocols for SAPALDIA and the European Community Respiratory Health Survey (ECRHS) (Burney et al. 1994) are similar (Tab. 1) and participants from the SAPALDIA Basle centre aged 18-44 in 1991 are also participants in the ECRHS study. Since ECRHS II was initiated slightly in advance of SAPALDIA 2, examinations at the Basle centre preceded those in other SAPALDIA centres. 
Informed consent
Ethical approval for SAPALDIA 2 was given by the central ethics committee of the Swiss Academy of Medical Sciences and the Cantonal Ethics Committees for each of the eight examination areas. The consent information provided to participants described the health examination including the bronchial challenge, the ambulatory electrocardiogram (ECG) and blood collection. Additionally there was information about data protection and the genetic assessments. Participants were required to give written consent before any part of the health examination was conducted and were provided with written consent information to read and were given the opportunity to ask questions about the examination. Subjects could either give global consent (for all health examinations) or agree to each investigation separately.
Documentation
All study documentation, including questionnaires and protocols, was provided in German, French and Italian because native languages differed between SAPALDIA centres. Documents were usually conceived in German or English and then translated in French and Italian. Translations were cross-checked in simultaneous readings with SAPALDIA research personnel who were native speakers of the respective languages and fluent in at least one of the other languages. This procedure had already been used in 1991 and at that time back-translations were also used for validation. As the majority of questionnaires were already available in the three languages, back-translations were unnecessary in SAPALDIA 2.
Interview administered main questionnaire
The interview was conducted by a trained fieldworker and answers from the participant were entered directly into an Access database on a personal computer. As in SAPALDIA 1, the interview included questions about history of respiratory symptoms, allergic diseases, general health, living and working environment, smoking habits, exposure to traffic, exposure to environmental tobacco smoke and animals. In SAPALDIA 2 the questionnaire was extended with additional questions about chronic diseases, including heart disease, questions about dietary habits (adapted from the Swiss Health Questionnaire (Bundesamt für Statistik 2001 Statistik /2004 , physical activity (derived from the ECRHS II-and the Swiss Health Questionnaire) and sleepiness (derived from the Epworth Sleepiness Scale (Johns 1991) ). Present and past medication use was recorded in detail; including type, dose, start date of medication use and duration. (Juniper et al. 1993 ) (given to the subjects who had answered "yes" to the question: "Have you ever had asthma?") and a women's questionnaire (with questions about menstruation, menopausal status and intake of hormones) (Tab. 1 and 3a). In addition, a card was handed to all pre-menopausal women with the request to send the card back with the date that their next menstrual cycle commenced in order to determine their hormonal status at the time of health examination. A job exposure matrix (Kennedy et al. 2000) was used to assess occupational exposures since SAPALDIA 1. Participants who had worked as cleaners (in a job and at home), nurses, metal workers, solderers, welders and participants who had worked with disinfectants were also asked to complete an occupational questionnaire specific to the occupational activity or exposure. Participants also completed an address/ ZIP code Blood pressure measurement Systolic and diastolic blood pressures were measured after the interview and after the participant had sat quietly for at least 10 minutes. Pressures were measured twice with an interval of at least 3 minutes using an automatic OMRON 705 CP (Tokyo, Japan) with the cuff attached to the naked left upper arm.
Collection and fractioning of blood samples
Blood samples were taken from all subjects who had consented to the general blood marker analyses and/or the genetic analyses. 45 ml of blood was collected for blood marker analysis into differently coated 9 ml Monovette tubes (SARSTEDT; Nuembrecht, Germany). EDTA-coated tubes were used for collection of blood, plasma and buffy coat, Lithium-Heparin-coated tubes for plasma collection and non-coated tubes for serum collection. With the exception of one EDTA-coated tube, the samples were centrifuged at room temperature (20°C, 15 min, 1500 g) using a UNIVERSAL 32 R centrifuge (Hettich AG, Baech, Switzerland). Subsequently the fractioned and EDTA-buffered whole blood samples were aliquoted (300 to 500 ml) into 1ml TPP Cryotubes (Trasadingen, Switzerland) and transferred to -80°C immediately. The blood sample collection and fractioning procedure was performed within a maximum of four hours. If possible, 40 aliquots were prepared per subject, (corresponding to 3 vials of buffy coat, 3 of EDTA-plasma, 4 of EDTA-buffered whole blood, 10 of Li-He-plasma, and 20 vials of serum). For DNA extraction, 7 ml of whole blood was collected in EDTA-coated Monovette tubes, which were stored without previous centrifugation at -80°C.
Constitution of the blood plasma, serum and DNA banks
The samples extracted from blood were stored in eight SANYO freezers (Applewood, ON, Canada) with a storage volume between 519 (U71V) or 728 litres (U50V) that were connected to emergency back-up systems (including an alarm system and/or CO2 backup). After completion of the data collection phase in spring 2003, all freezers were transported to one location (University Hospital, Geneva) for sample sorting. The blood bank containing about 250 000 blood aliquots was split into two identical banks. For reasons of security and accessibility the two bio banks are now located in two different centres for long-term storage (University Hospitals of Geneva and Zurich). During the transport, inside freezer temperatures were monitored and did not increase above -60 o C at any time. The whole blood samples taken for genetic analysis were transferred on dry ice to the laboratory performing the DNA extraction (Departments of Molecular Epidemiology and of Medical Molecular Genetics, University of Zürich). The blood samples were processed manually using the PUREGENE TM DNA Purification Kit (GENTRA Systems, Minneapolis, USA). The observed DNA yields ranged from 7-80 µg of DNA obtained from 1 ml of frozen EDTAbuffered blood. Quality of genomic DNA was evaluated in terms of DNA degradation visually on 0.8 % agarose gel electrophoresis and in terms of purity by performing standard and allelespecific PCR amplification. Subsequently, DNA working solutions were generated by diluting the DNA with milli-Q-pure water and concentration was adjusted to 10 ng/µl. Barcode-labelled 2 ml tubes with screw-caps (SARSTEDT; Nuembrecht, Germany) were used to store DNA stock and working solutions. DNA working solutions were kept at -20°C for long-term and 4°C for short-term storage. In analogy to the blood specimen bank, the DNA stock solutions were transferred for accessibility and security reasons to two locations (Zurich and Geneva). A computer-based data bank (Excel format) was established, containing an identification code for each participant, coordinates identifying the location of each type of biological sample (serum, both type of plasma, buffy coat, whole blood, and DNA), the number of vials present, DNA extraction remarks, concentration and volume of available DNA stock solution, DNA quality characteristics and the location of the diluted DNA working solution.
Weight and height measurements
The participants were asked to remove all heavy clothes such as shoes, jacket, coat etc. For the height assessment, telescopic scales, model 222, from SECA (Hamburg, Germany) were used. The scale was permanently fixed unto the wall and the participant was required to make contact to the wall with the backside of his head, the upper back, the rear, the lower legs as well as with his heels during the measurement. An electronic scale (T160-T620-T630) from TERRAILLON (Bradford, MA, USA) was used for the weight measurements. Weight was displayed digitally in kilograms to one decimal point. The scales were calibrated with standardised weights at regular intervals. The height scales were checked during quality assessment visits.
Carbon monoxide measurement
In order to validate participants answers to smoking habits end-expiratory carbon monoxide (CO) was measured with EC50 Micro-Smokerlyzer, (BEDFONT, Rochester, UK). Participants were asked to first completely exhale, then to inhale fully, to hold their breath for at least 20 seconds and finally exhale completely through the mouthpiece of the measuring device. CO devices were calibrated approximately every six months.
Spirometry
The same spirometers based on an open system using a mass flow anemometer (Sensormedics model 2200, Yorba Linda, USA), meeting American Thoracic Society (ATS) performance criteria, were used in both SAPALDIA 1 and 2. A quality assessment in 2001 demonstrated that measurement of lung volumes by the eight spirometers were comparable to one another (Kuna-Dibbert et al. 2005) . The same spirometry protocol was followed in SAPALDIA 1 and 2 that was identical to the protocol in ECRHS (Künzli et al. 1995) . Spirometers were calibrated twice a day using a standardised three litre syringe. Participants performed manoeuvres in a sitting position wearing nose clips. At least three and up to maximal eight forced expiratory lung function manoeuvres were performed in order to obtain a minimum of two acceptable results for for both FEV 1 and FVC and the forced expiratory flows (FEF 25 , FEF 50 , and FEF 75 ) were recorded from each manoeuvre. Flowvolume curves and codes indicating compliance with American Thoracic Society criteria were displayed on computer screen as each manoeuvre was performed (American Thoracic Society 1995) to assist the technicians in the selection of acceptable manoeuvres. Spirometry technicians were also required to report problems during the test that could affect quality of trials. Expiratory flow measures were taken from the flow-volume curve with the highest sum of FVC and FEV 1 . As in SAPALDIA 1, all spirometry outputs were visually screened by respiratory physicians experienced in lung function testing. There were 370 flow-volume curves from 237 participants excluded because of abnormalities that indicated technical problems during the performance of the manoeuvre (Townsend et al. 2004) .
Methacholine bronchial challenge
Non-specific bronchial responsiveness was assessed by bronchial challenge with methacholine chloride in participants able to produce satisfactory spirometry, and who fulfilled health criteria. Participants were excluded if they had had a myocardial infarction in the last 12 months, were taking medication for heart disease, had epilepsy, were pregnant, were lactating and/or were receiving treatment with any beta blockers including eye drops. The protocol followed in SAPALDIA 2 was identical to that in SAPALDIA 1. Methacholine (PROVOCHOLINE ® , Methapharm Inc., ON, Canada) was administered by MEFAR aerosol dosimeters (Anandic Medical Systems, Diessenhofen, CH) starting with inhalation of physiological sodium chloride (NaCl) followed by increasing concentrations of methacholine up to a cumulative dose of 2 mg. The dosimeter was triggered automatically at the beginning of the inhalation and the subjects were instructed to hold their breath at full inspiration for four seconds. Between one and two minutes after the end of each inhalation two FEV 1 manoeuvres were performed and the manoeuvre with the highest FEV 1 recorded. The test was stopped when either the cumulative dose of 2 mg had been reached or FEV 1 had fallen by 20 % or more compared to the NaC l baseline value or the participant refused to continue. A bronchodilator (Salbutamol ® , 200 mg) was offered to participants who experienced a drop in FEV 1 during the challenge. Seven new Mefar nebulisers were purchased for SAPALDIA 2. All nebulisers were calibrated in 2001 by the manufacturers in Melbourne Australia. Driving pressures from the Mefar dosimeters were checked periodically at the centres using a manometer. All challenge tests were assessed for compliance with the study protocol.
hour Holter electrocardiogram (ECG)
Only participants aged 50 and older were eligible for a 24 hour electrocardiogram (ECG) monitoring with a Holter recorder (Aria, Del Mar Medical Systems, Irvine California). Exclusion criteria included having a cardiac pacemaker, having undergone anaesthesia during the previous eight days or having taken anti-arrythmic drugs class I or III or digitalis glycosides within the last 30 days. The Holter monitor was fitted by placing one of three electrodes (Blue Sensor, Medicotest, Stykke, Denmark) 2 cm to the right of processus xiphoideus, another electrode on the left linea medioclavicularis on the lowest rib and the third electrode was located on the left front axillar line on the lowest rib. During the ambulatory ECG monitoring period, participants completed a location and activity diary derived from a diary previously developed for the EXPOLIS study (Jantunen et al. 1998) . The SAPALDIA ECG diary contained fields for recording information on the participants whereabouts (indoor, outdoor etc), levels of activity, caffeine and alcohol use, consumption of tobacco (active and passive) and medication for every 15 minute interval during the monitoring period.
Quality control procedures
Instruction protocols for all methods and parts of the study were prepared in a written form. Fieldworkers participated in a three day training workshop, before the beginning of the study. Each fieldworker was required to test at least 10 volunteers at the centre under supervision before starting to examine participants. Three additional workshops for fieldworkers were held during the data collection period to assure high data quality. In addition, quality control visits to all eight centres were conducted three times during the examination phase. At each visit at least one full examination was observed and possible improvements were discussed with the fieldworkers. Furthermore, compliance with required standardised operating procedures was checked and oral and written feedback provided. Moreover, differences in the quality between fieldworkers and centres in the conduct of spirometry were assessed in detail and reported back to the fieldworkers. The quality control visits also offered a platform for feedback from the local teams about the participation rates and quality of the recorded data received by the central coordinating team. During the data collection period, six SAPALDIA bulletins with information and feedback were distributed to all centres. The bulletins addressed issues relating to data collection and quality and provided additional information about topics that had been raised during workshops and quality control visits.
Environmental data
In each SAPALDIA region, criteria gases (NO 2 , SO 2 , ozone) and fine particles (PM 10 , PM 2.5 ) have been monitored at central sites. The core of these air pollution measurements have been conducted within the national (NABEL) and cantonal monitoring networks, providing long-term routine data for six of the eight SAPALDIA regions. Measurements initiated by SAPALDIA closed the gaps in the monitoring network (Montana and Wald) and regarding parameters not routinely assessed (PM 2.5 ). Air quality standards for PM 10 were introduced in Switzerland in 1996 making measurement of PM 10 mandatory. Measurement of PM 10 by Harvard impactors was introduced in the SAPALDIA regions already in 1993. The changes in PM 10 measuring technologies since then have been taken into account for calculating PM 10 time series between 1991 and 2002. Annual means of PM 10 before 1997 could be esti-mated as fraction of total suspended particulates (TSP) (Gehrig & Hofer 1999) in Geneva, Lugano, Basel, Payerne and Davos, while in Wald and Montana Harvard impactor data was converted to the reference method Digitel HiVol sampling (Monn & Krütli 1999) . PM 2.5 has been measured in all SAPALDIA areas since 1999. Personal, indoor and outdoor NO 2 has been measured by SAPALDIA participants in 1992/93 using palmes tubes (Monn et al. 1998 ) and indoor and outdoor NO 2 again in 2002/03. In addition to air pollutants, meteorological parameters and pollen data have been collected for each SAPALDIA area. In SAPALDIA 1, exposure assignment relied predominantly on data from a single monitor in each community. Most participants lived within seven kilometers of the local monitoring stations and we had demonstrated that particulate matter, one of our primary indicators of ambient air pollution, is homogeneously distributed within such distances and not much affected by local traffic (Röösli et al. 2000; 2001) . Moreover, we have found ambient PM 2.5 from outdoor sources to be correlated with personal exposure to PM 2.5 (Oglesby et al. 2000) . As indicator of spatially less homogenous traffic-related pollutants, we chose NO 2 as primary candidate, and conducted complementary neighborhood monitoring in SAPALDIA1. The latter showed associations with lung function within areas not observed with PM 10 (Schindler et al. 1998). In SAPALDIA 2 the single monitor approach was extended towards individual exposure estimates. The goal is the assignment of individual long-term air pollution exposure to each subject, taking into account changes in residential location during the 11 year follow-up period. Approximately 20% of SAPALDIA 2 participants moved from their original study area in SAPALDIA 1. Therefore, estimates of ambient concentrations of air pollutants from other areas need to be incorporated into exposure estimates. Exposure estimates for SAPALDIA 2 participants will be derived from NO 2 , PM 10 and PM 2.5 maps resulting from emission-based models using Geographical information system technology (GIS) which have been validated by monitoring data from fixed sites. The model for NO 2 will be further validated and, if necessary, adjusted using outdoor NO 2 palm tubes measurements made by sub-samples of SAPALDIA 1 and SAPALDIA 2 participants at their homes and GIS-data on traffic-related parameters such as distance to street. The resulting models of ambient pollutant levels over the follow-up period will then be linked to the residential locations of SAPALDIA participants thereby providing individual exposure estimates.
Results

Participation in examinations
In 1991, 9 651 subjects participated in SAPALDIA 1. By 2001, 283 (2.9 %) participants had died (194 men, 89 women), 653 (6.8 %) had moved abroad or were not traceable by March 2003. Therefore, 8 715 subjects (93 % of the survivors of the original cohort) could be contacted (Tab. 2). Of these 8 715 subjects, 8 047 (92 % or 86 % of survivors) completed at least one questionnaire (screening questionnaire, main interview questionnaire or short versions of the main interview questionnaire). Participants who provided more information than the screening questionnaire were classified as responders and as having participated in SAPALDIA 2 (N=7 680=88 % of traceable and 82 % of living participants in 2001) (Tab. 3a). There were 6 528 SAPALDIA 2 participants who performed spirometry and of these 6 222 provided spirometry data that met quality criteria. For the methacholine challenge test, 167 participants (2.6 %) had to be excluded on the basis of an FEV1 less than 70 % of predicted or less than 1.5L. Other participants were excluded on the basis of having had a myocardial infarction within the last three months, receiving medication for heart disease, pregnancy, lactation, treatment with beta blockers (13.3 %), no consent for testing (7.3 %), and other reasons which included doubts about health status of the participant, unsatisfactory manoeuvres, technical problems and loss of data (8.2 %). Of the 4 655 participants who had a bronchial challenge; data from 4211 (90.5 %) participants met quality criteria. We collected blood samples of 6 327 participants who agreed to blood marker analysis and extracted DNA from blood of 6 215 participants who agreed to genetic testing. Of the random sample of older participants invited to participate in the measurement of ECG; 1 860 provided an ECG for a continuous period of more than 20 hours. Table 3 a and b give an overview on participation in examinations and the numbers of questionnaires of different types. There were 6 207 subjects, representing 66 % of the survivors of the original cohort, who completed the entire protocol (interview, spirometry and blood sample); and valid data is available for 5 973 (62 %).
Description of participants in SAPALDIA 1 and 2
To test the hypothesis that participation was associated with health-related behaviours (e. g. smoking) and health status (e. g. lung function and symptoms), we compared participants in both SAPALDIA 1 and 2 to participants who only participated in SAPALDIA 1 using data collected at SAPALDIA 1. Figures 1a and 1 b show the prevalence of never and current smokers and selected respiratory symptoms in participants in SAPALDIA 1 and SAPALDIA 2. An adjusted means procedure was utilised to show the prevalence in SAPALDIA 2 adjusted for smoking and symptom characteristics of all participants in SAPALDIA 1 (STATA Corporation, Texas 77845, Special Edition release 8.2). Overall, participants in both SAPALDIA 1 and 2 had slightly less symptoms in 1991 and were more likely to be nonsmokers than those who did not participate in the follow-up. As expected there was a small increase in prevalence of some respiratory symptoms, specially wheeze and classic phlegm, and a considerable proportion (28 %) of smokers had quit smoking. Tables A1 and A2 in the appendix show the distribution of BMI by age groups and sex. There was a considerable increase of weight in this population between assessments (the mean weight increase was 5.5 kg/person). The mean Ackermann-Liebrich U, Kuna-Dibbert B, Probst-Hensch NM, et al. Follow-up of SAPALDIA 2, 1991 -2003 1) Interview includes subjects who answered either the long, short or ultra-short interview questionnaires and excludes subjects who only answered the screening questionnaire 2) Spirometry that met good quality criteria 3) Methacholine challenge that met good quality criteria 4) "Complete" examinations meeting quality criteria weight gain was highest in younger men and decreased in both sexes after 55. The Tables in the Appendix also show the distribution of lung function (measured by forced expiratory volume in one second and forced vital capacity), the prevalence of the selected respiratory symptoms as well as the prevalence of current smoking and amounts of cigarettes smoked per day.
Development of air pollutants between SAPALDIA 1 and 2
Ambient concentrations of NO 2 and PM 10 have decreased in most SAPALDIA areas since 1991 (Fig. 2a and 2b) . In most areas the strong decrease of the early 1990s was partially levelled out by increasing levels due to meteorological factors in the years just before SAPALDIA 2, particularly for PM 10 . The strongest absolute decline of NO 2 was observed in the two areas with the highest 1991 baseline levels, Geneva and Lugano, while the alpine area Montana exhibited on a low level a slight increase. The absolute and relative decline of PM 10 in most areas was less pronounced compared to NO 2 . Differences between the areas remain, especially for NO 2 , though the air pollution exposure contrast between areas has been reduced since SAPALDIA 1.
Discussion
Despite a demanding study protocol, a high participation rate was achieved in the SAPALDIA follow-up. Comparison of characteristics at SAPALDIA 1 showed some differences between SAPALDIA 2 participants and non-participants, but most differences were small and are unlikely to bias the main analyses of the study. The SAPALDIA cohort gained weight in the past 11 years. The average increase in body mass index (BMI) in young men was 3.7 kg/m 2 , on average subjects weighed 5.5 kg [SE 0.08] more than in 2002 compared to 1991. The distribution of BMI in the SAPALDIA population compares favourably to the MONICA Augsburg population (Gasse et al. 2002) and the Chianti population (Bartali et al. 2002) , within both sexes and across all age groups, although women in Innsbruck seem to be slimmer (Ulmer et al. 2001) . The BMI reported by Schilling (Schilling et al. 2001) for Swiss employees seems comparable to the distribution for women in our study, but as their results relate to the years 1996-98 one might speculate that the distribution of BMI in their population might also have been higher in 2002. As for the amount of cigarettes smoked, an interesting comparison with the Innsbruck Women's Health Study (Ulmer et al. 2001 ) is possible. While the proportion of smokers is considerably higher in Innsbruck (40% in the youngest age group and 35% in women aged 40-59) the mean number of cigarettes smoked per day is higher in the Swiss female population. Since these results from SAPALDIA 2 are consistent with data from other Swiss surveys and prevalence estimates for symptoms from SAPALDIA 2 did not change much after adjustment for differential non-participation we conclude that the SAPALDIA population sample reflects the distribution of risk factors for non communicable diseases in an average Swiss population. SAPALDIA was designed to investigate the effects of air pollutants on respiratory health (including lung function, development of symptoms and diseases) in a random sample of the adult population of Switzerland. Given the high participation rate in the SAPALDIA follow-up we have sufficient power to test the association of respiratory, allergic and cardiovascular outcomes with air pollution parameters over the course of 11 years. In SAPALDIA 2, the urban centres Basel and Geneva had lower participation rates. We therefore expect that the trend towards healthier more educated participants is amplified in these cities, which might result in an under-estimation of the effects of ambient air pollution, since they might live in less polluted places. However since we are able to look at differences within individuals as well as by area sampling effects by area become less important. Throughout the 11 year follow-up period air quality has been continuously monitored and a steady decline in most pollutant levels has been observed. The individual long term exposure assignment (based on personal residential history and GIS modelling of air pollutant concentrations) will increase power to detect the effects of ambient air pollution at different levels of cumulative exposure (Künzli & Tager 2000) . These improvements in individual exposure assignment should counterbalance the relative loss in power due to the steady decrease in pollution levels which ultimately reduces the exposure contrast in the SAPALDIA study. The DNA collected in the follow-up will enable us to address emerging questions about the interaction of environmental and genetic factors in important diseases and might help to detect especially sensitive subgroups. 
